People's Hospital of Cangzhou

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

AP-1-IL-1β signaling pathway on impulsive-like behavior and memory deficits in aged mice under tibial plateau fracture conditions

Tibial fracture surgery has attracted significant interest as a notable trigger for PND. Under external stimuli such as anesthesia and surgery, the transcription factor AP-1 regulates the abnormal expression of glutamatergic neurons via interleukin-1β (IL-1β), a mechanism closely...

Post-injury high-sensitivity C-reactive protein to lymphocyte ratio and nonunion risk in adult extremity fractures: evidence from a multicenter retrospective cohort

Early immuno-inflammatory response serves a critical role in the process of fracture healing, and both excessive and insufficient activation after injury may predict adverse outcomes. This study aimed to investigate the association between post-injury high-sensitivity C-reactive...